Deep knowledge on
small-molecule drugs and
the 90,000 global patents
|Title:||Intermediate release nicotinic acid compositions for treating hyperlipidemia|
|Abstract:||Intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, such as Cmax, Tmax and AUC, which are suitable for oral administration once per day during the evening or at night for treating hyperlipidemia without causing drug-induced hepatotoxicity to such a level that requires the therapy to be discontinued, are disclosed. The intermediate nicotinic acid formulations can be administered as tablets in dosage strengths of, for example, 375 mg, 500 mg, 750 mg and 1000 mg.|
|Inventor(s):||Cefali; Eugenio A. (Fort Lauderdale, FL), Bova; David J. (Boca Raton, FL)|
|Assignee:||KOS Pharmaceuticals, Inc. (Miami, FL)|
Patent Claim Types:|
see list of patent claims
|Use; Formulation; Compound; Dosage form;|
|Country||Document Number||Publication Date||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Canada||2591710||Sep 11, 1998|
|Australia||6454598||Sep 22, 1998|
|Canada||2574987||Sep 11, 1998|
|Austria||289197||Mar 15, 2005|
|Norway||994275||Sep 02, 1999|
|This preview shows a limited data set|
Subscribe for full access, or try a free trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.